Mona Sazgar, MD
Epilepsy · Orange, CANPI 1215909486
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $169,784 of the $222,117 with a category attached, or 76.4%. 12 manufacturers reported payments, led by UCB, Inc. at 34.1% of the total. Reporting peaked in 2022 at $70,674 and has fallen 78.7% since, to $15,045 in 2025. Among epilepsy clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 317 payments — averaging $700.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$76K
- SK Life Science, Inc.$60K
- Eisai Inc.$44K
- Neurelis, Inc.$37K
- Neuropace, Inc.$3K
- Jazz Pharmaceuticals Inc.$656
- plus $2K from 6 others
Across 43 payments — averaging $2807.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$77K
- Sunovion Pharmaceuticals Inc.$25K
- UCB Biosciences Inc.$10K
- Biogen$9K
What the payments were for
- Consulting fees$27,18012%
- Speaking & faculty fees$169,78476%
- Travel & lodging$15,1327%
- Food & beverage$10,0085%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 109 | $75,783 |
| SK Life Science, Inc. | 77 | $60,205 |
| Eisai Inc. | 46 | $44,079 |
| Neurelis, Inc. | 38 | $36,778 |
| Neuropace, Inc. | 25 | $2,727 |
| Jazz Pharmaceuticals Inc. | 7 | $656 |
| Sunovion Pharmaceuticals Inc. | 4 | $646 |
| Aquestive Therapeutics, Inc. | 2 | $545 |
| Livanova USA, Inc. | 1 | $295 |
| Catalyst Pharmaceuticals, Inc. | 2 | $249 |
| Greenwich Biosciences, Inc. | 1 | $145 |
| Travere Therapeutics, Inc. | 5 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XCOPRI$57,720
- Fycompa$43,852
- Briviact$42,571
- VALTOCO$36,360
- Nayzilam$14,450
- Fintepla$3,288
- RNS Neurostimulator Kit$2,030
- Epidiolex$671
- APTIOM$495
- VNS Therapy$295
- SYMPAZAN$125
- RNS System$105
How this compares
$222,117 in reported general payments places this provider in the 95th percentile of 46 epilepsy providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpidiolexCannabidiol (Cbd) | 55 | $305,260 |
| FinteplaFenfluramine Hcl | 13 | $256,205 |
| BriviactBrivaracetam | 143 | $223,662 |
| XcopriCenobamate | 102 | $137,996 |
| Vigabatrin | 12 | $103,713 |
| Qudexy XrTopiramate | 13 | $76,837 |
| LamictalLamotrigine | 25 | $53,335 |
| FycompaPerampanel | 40 | $51,276 |
| VimpatLacosamide | 40 | $47,585 |
| Rufinamide | 33 | $40,897 |
| OnfiClobazam | 16 | $38,573 |
| Felbamate | 46 | $35,697 |
| Topiramate ErTopiramate | 18 | $33,055 |
| NayzilamMidazolam | 39 | $25,960 |
| Keppra XrLevetiracetam | 12 | $20,056 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Fintepla, Briviact, Vimpat, Nayzilam | $75,783 | $553,413235 claims |
| SK Life Science, Inc.Xcopri | $60,205 | $137,996102 claims |
| Eisai Inc.Fycompa | $44,079 | $51,27640 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 46 epilepsy providers in California.
Other epilepsy in Orange
- David King StephensOrange$551K
- Kurt QingOrange$7K
- Lilit MnatsakanyanOrange$3K
- Brian JungOrange$3K
- Doris DengOrange$3K
- Josef ParviziStanford$438K
- Kimford MeadorStanford$50K
- Robert FisherStanford$41K
- Martha MorrellStanford$17K
- George NuneArcadia$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.